- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- April 2024
- 293 Pages
Global
From €4778EUR$4,950USD£4,098GBP
- Report
- July 2023
- 253 Pages
Europe
From €2027EUR$2,100USD£1,739GBP
€2896EUR$3,000USD£2,484GBP
- Report
- April 2024
- 175 Pages
From €4826EUR$5,000USD£4,140GBP
- Report
- July 2022
- 100 Pages
Global
From €2654EUR$2,750USD£2,277GBP
- Report
- April 2018
Global
From €4343EUR$4,500USD£3,726GBP
- Report
- December 2021
- 121 Pages
Global
From €4295EUR$4,450USD£3,684GBP
- Report
- November 2018
- 106 Pages
Global
From €4295EUR$4,450USD£3,684GBP
- Report
- April 2018
- 99 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- August 2023
- 96 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- August 2023
- 96 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- January 2022
- 117 Pages
Global
From €4343EUR$4,500USD£3,726GBP
The Blood Component market is a subset of the biopharmaceutical industry that focuses on the production and distribution of blood components, such as red blood cells, platelets, and plasma. These components are used to treat a variety of medical conditions, including anemia, cancer, and trauma. The market is highly regulated, with stringent safety and quality standards in place to ensure the safety of the products.
The Blood Component market is a highly competitive space, with a number of companies vying for market share. Some of the major players in the market include Grifols, CSL Behring, Octapharma, Kedrion, and Biotest. Show Less Read more
